KLK3 and benign prostatic hyperplasia: In a four-year clinical trial, Roehrborn et al. compared the influence of baseline PV and PSA on the incidence of AUR, BPH-related surgery, and overall clinical progression in 4844 men treated with tamsulosin, dutasteride, or a combination of both drugs.